Phase II study of the combination of bevacizumab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma (NB)

Category Primary study
JournalJournal of Clinical Oncology
Year 2016
This article has no abstract
Epistemonikos ID: 02422e3b83d0cd2492a6b910c16fc7677483c9c2
First added on: Feb 07, 2025